吉非替尼联合卡培他滨对复发转移三阴性乳腺癌的疗效分析  

Clinical study of gefitinib plus capecitabine in treatment of recurrent and metastatic triple negative breast cancer

作　　者：吴骥[1] 郑向欣[1] 顾书成 袁牧[1] 侍孝红[2] 陈雷 管小青[1] 

机构地区：[1]江苏省南京鼓楼医院集团宿迁市人民医院甲乳外科,宿迁223800 [2]江苏省南京鼓楼医院集团宿迁市人民医院病理科,宿迁223800 [3]江苏省南京鼓楼医院集团宿迁市人民医院肿瘤内科,宿迁223800

出　　处：《中华内分泌外科杂志》2017年第5期369-372,共4页Chinese Journal of Endocrine Surgery

基　　金：江苏省宿迁市指导性科技计划项目（Z201224）

摘　　要：目的观察吉非替尼联合卡培他滨对复发转移三阴性乳腺癌的疗效与安全性。方法收集2011年1月至2016年6月间于江苏省南京鼓楼医院集团宿迁市人民医院经辅助治疗后出现复发转移的三阴性乳腺癌患者41例，根据患者的意愿分为2组，观察组给予吉非替尼联合卡培他滨治疗共24例；对照组给予卡培他滨单药口服共17例。2组均连续随访12个月，用药直至疾病进展或因毒性不可耐受。结果观察组和对照组的客观有效率（objective response rate,ORR）分别为70．83％（17／24）和35．29％（6／17），疾病控制率（disease control rate,DCR）分别为91．67％（22，24）和64．71％（11／17），2组相比差异有统计学意义（P〈0．05）。2组的总体不良反应发生率相当，组间差异无统计学意义（P〉0．05），患者均能耐受。结论吉非替尼联合卡培他滨治疗复发转移三阴性乳腺癌有一定疗效，不良反应轻，部分患者能获得超过12个月的生存期，值得进一步研究。Objective To evaluate the efficacy and safety of gefitinib plus capecitabine in treatment of recurrent and metastatic triple negative breast cancer. Methods From Jan. 2011 to Jun., 41 patients who have recurrent and metastatic triple negative breast cancer after treated by adjuvant chemotherapy were enrolled in this study They were divided into two groups according to their wishes. The 24 cases in the experimental group were treated with gefitinib plus capecitabine. The 17 cases in the control group were treated with capecitabine. The two groups were followed up for 12 months. They were treated until the disease progression or the toxicity could not be tolerated. Results The objective response rate （ORR） in the experimental group and the control group was 70.83%（17/24） vs 35.29%（6/17）. The disease control rate （DCR） in the two groups was 91.67% （22/24） vs 64.71% （11/17）. The difference between the two groups was statistically significant （P〈0.05）. The incidence rate of adverse drug reactions in the two groups was similar （P〉0.05）, and the reactions were tolerable. Conclusion Gefitinib plus capecitabine is an effective and safe treatment for recurrent and metastatic triple negative breast cancer with tolerable adverse reactions, and some patients were able to survive for more than 12 months.

关 键 词：吉非替尼 卡培他滨 复发转移 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]